Why Invest in Genflow Biosciences
Founded in 2020, Genflow Biosciences Ltd, a UK-based biotech firm with research and development facilities in Belgium, is dedicated to discovering and advancing new therapeutic approaches to halt or slow the ageing process for longer, healthier lives. Genflow Biosciences’ lead compound, GF-1002, operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
Extending Healthspan and Lifespan with Groundbreaking Science
Genflow Biosciences is focused on developing and commercializing innovative therapies that target the ageing process in both humans and dogs. Our goal is to halt or delay the onset of ageing, which will lower healthcare expenditures and ease the emotional and social challenges associated with an ageing population by directly intervening in the process.
